NewsRelease
ProteomicsResearch Article Cites HemogloBind™in Profiling Lung Injury
MONMOUTHJUNCTION, NJ, September7, 2016 -- Biotech Support Group reports on a recent research articledescribing the describingthe simplicity and efficiency of their hemoglobin depletiontechnology for improving the proteomic information obtained frombronchoalveolar lavage fluid (BALF). The citation is:
ManeeshBhargava,KevinJ. Viken,SanjoyDey,MichaelS. Steinbach,BaolinWu,PratikD. Jagtap,LeeAnnHiggins, AngelaPanoskaltsis-Mortari,DanielJ. Weisdorf,VipinKumar,MuktaArora,PeterB. Bitterman,DavidH. Ingbar,ChrisH. Wendt.ProteomeProfiling in Lung Injury after Hematopoietic Stem CellTransplantation. BiolBlood Marrow Transplant 22 (2016) 1383-1390.http://www.bbmt.org/article/S1083-8791(16)30060-X/fulltext
Theauthors consider pulmonary complications due to infection andidiopathic pneumonia syndrome (IPS) in hematopoietic stem celltransplant (HSCT) recipients. For this, a proteomic characterizationof global bronchoalveolar lavage fluid (BALF) was studied to identifyproteins and pathways that differentiate IPS from infectious lunginjury after HSCT. Because the BALF samples appeared tinged withblood, the authors tested HemogloBind™ to determine whether theremoval of hemoglobin (in addition to high-abundance proteins) wouldimprove the depth of coverage. The article states “Hemoglobinremoval improved protein identification to 845 proteins at 1% globalFDR compared with 496 proteins with high-abundance protein depletionalone”. The authors conclude that the protein expressiondifferences provide insights into mechanisms activated in lung injuryand suggest potential therapeutic targets to augment lung repair.
“Iam very pleased that this article demonstrates the proteomic utilityof removing hemoglobin from tissue samples containing small amountsof blood. It is very impressive that the use of HemogloBind™improved the depth of coverage by almost 2-fold” states Swapan Roy,Ph.D., President and Founder of Biotech Support Group.
Formore information on HemogloBind™,visit:
http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information,go to http://www.biotechsupportgroup.com
Contact:
Dr.Swapan Roy & Matthew Kuruc
BiotechSupport Group LLC
1Deer Park Drive, Suite M
MonmouthJunction NJ 08852
732-274-2866Worldwide
800-935-0628NorthAmerica
[email protected]
http://www.biotechsupportgroup.com
